Farwell JR, Dohrmann GJ, Flannery JT (1977) Central nervous system tumors in children. Cancer 40(6):3123–3132

Article  PubMed  CAS  Google Scholar 

Ostrom QT et al (2021) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2014–2018. Neuro Oncol 23(12 Suppl 2):iii1–iii105

Article  PubMed  PubMed Central  Google Scholar 

Ostrom QT et al (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol 22(12 Suppl 2):iv1–iv96

Article  PubMed  PubMed Central  Google Scholar 

Calò P et al. (2023) Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma. Cancers (Basel) 15(4)

Marquet G et al (2007) Grading glioma tumors using OWL-DL and NCI Thesaurus AMIA Annu Symp Proc, 2007: pp 508 – 12

Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

Article  PubMed  Google Scholar 

Jaeckle KA et al (2011) Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol 104(1):253–259

Article  PubMed  CAS  Google Scholar 

Oberheim Bush NA, Chang S (2016) Treatment strategies for low-grade glioma in adults. J Oncol Pract 12(12):1235–1241

Article  PubMed  Google Scholar 

de Blank P et al (2019) Management of pediatric low-grade glioma. Curr Opin Pediatr 31(1):21–27

Article  PubMed  PubMed Central  Google Scholar 

Green K et al (2023) A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: safety, efficacy, visual morbidity, and outcomes. Neuro Oncol 25(4):774–785

Article  PubMed  CAS  Google Scholar 

Wisoff JH et al (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68(6):1548-54; discussion 1554-5

Ater JL et al (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30(21):2641–2647

Article  PubMed  PubMed Central  Google Scholar 

Gnekow AK et al (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol 14(10):1265–1284

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shaw EG, Wisoff JH (2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol 5(3):153–160

Article  PubMed  PubMed Central  Google Scholar 

Habibi MA et al (2022) The efficacy and safety of rituximab in ANCA-associated vasculitis: a systematic review. Biology 11(12):1767

Article  PubMed  PubMed Central  CAS  Google Scholar 

Habibi MA et al (2024) The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis. Eur J Clin Pharmacol 80(5):639–656

Article  PubMed  CAS  Google Scholar 

Baumgarten P et al (2016) Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and – 3 and co-receptors neuropilin-1 and – 2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol 18(2):173–183

Article  PubMed  CAS  Google Scholar 

de Marcellus C et al (2022) The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. J Neurooncol 157(2):355–364

Article  PubMed  Google Scholar 

Møller S et al (2012) A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol 51(6):797–804

Article  PubMed  Google Scholar 

Bennebroek CAM et al. (2022) Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study. Cancers (Basel) 14(24)

Zhukova N et al (2019) Use of Bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. Cancer Med 8(1):40–50

Article  PubMed  CAS  Google Scholar 

Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Cosnarovici MM, Cosnarovici RV, Piciu D (2021) Updates on the 2016 World Health Organization classification of pediatric tumors of the central nervous system - a systematic review. Med Pharm Rep 94(3):282–288

PubMed  PubMed Central  Google Scholar 

Packer RJ et al (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52(7):791–795

Article  PubMed  Google Scholar 

Hwang EI et al (2013) Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 60(5):776–782

Article  PubMed  CAS  Google Scholar 

Gururangan S et al (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas–a Pediatric Brain Tumor Consortium study. Neuro Oncol 16(2):310–317

Article  PubMed  CAS  Google Scholar 

Kalra M et al (2015) Confirmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma. J Pediatr Hematol Oncol 37(6):e341–e346

Article  PubMed  CAS  Google Scholar 

Gorsi HS et al (2018) Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: a single institutional experience. Pediatr Blood Cancer 65(9):e27234

Article  PubMed  Google Scholar 

Roux C et al (2021) Metronomic maintenance with weekly vinblastine after induction with bevacizumab-irinotecan in children with low-grade glioma prevents early relapse. J Pediatr Hematol Oncol 43(5):e630–e634

Article  PubMed  CAS  Google Scholar 

Lu VM et al (2020) Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates. Neurooncol Pract 7(4):359–368

PubMed  PubMed Central  Google Scholar 

Bouffet E et al (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30(12):1358–1363

Article  PubMed  CAS  Google Scholar 

Gajjar A et al (2015) Pediatric brain tumors: innovative genomic information is transforming the Diagnostic and Clinical Landscape. J Clin Oncol 33(27):2986–2998

Article  PubMed  PubMed Central  CAS  Google Scholar 

Qaddoumi I, Sultan I, Broniscer A (2009) Pediatric low-grade gliomas and the need for new options for therapy: why and how? Cancer Biol Ther 8(1):4–10

Article  PubMed  CAS  Google Scholar 

Wang H et al (2021) Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis. BMJ Open 11(12):e048975

Article  PubMed  PubMed Central  Google Scholar 

Thomale UW et al (2004) Long-term follow-up of surgical intervention pattern in pediatric low-grade gliomas: report from the German SIOP-LGG 2004 cohort. J Neurosurg Pediatr p.1–14

Myung JK et al (2012) IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep 28(5):1639–1644

Article  PubMed  CAS